MCID: PRC016
MIFTS: 64

Pre-Eclampsia

Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pre-Eclampsia

MalaCards integrated aliases for Pre-Eclampsia:

Name: Pre-Eclampsia 12 43 44 15 70
Preeclampsia 12 73 43 58 29 54 6 17
Hypertension, Pregnancy-Induced, Susceptibility to 29 6
Pregnancy Associated Hypertension 12 70
Gestational Hypertension 12 15
Proteinuric Hypertension of Pregnancy 12
Gestational Proteinuric Hypertension 43
Transient Hypertension of Pregnancy 70
Hypertension Induced by Pregnancy 12
Preeclampsia, Susceptibility to 6
Pregnancy-Induced Hypertension 43
Pre-Eclamptic Toxaemia 12
Preeclampsia/eclampsia 12
Toxaemia of Pregnancy 12
Toxemia of Pregnancy 43
Pregnancy Toxemia 12

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:10591
MeSH 44 D011225
NCIt 50 C85021
SNOMED-CT 67 6758009
ICD10 32 O13 O14 O14.9
ICD10 via Orphanet 33 O14.0 O14.1 O14.2 more
UMLS via Orphanet 71 C0032914
Orphanet 58 ORPHA275555
UMLS 70 C0032914 C0341934 C0852036

Summaries for Pre-Eclampsia

MedlinePlus Genetics : 43 Preeclampsia is a complication of pregnancy in which affected women develop high blood pressure (hypertension); they can also have abnormally high levels of protein in their urine (proteinuria). This condition usually occurs in the last few months of pregnancy and often requires early delivery of the infant. However, this condition can also appear shortly after giving birth (postpartum preeclampsia).Many women with mild preeclampsia do not feel ill, and the condition is often first detected through blood pressure and urine testing in their doctor's office. In addition to hypertension and proteinuria, signs and symptoms of preeclampsia can include excessive swelling (edema) of the face or hands and a weight gain of more than 3 to 5 pounds in a week due to fluid retention. Affected women may also experience headaches, dizziness, irritability, shortness of breath, a decrease in urination, upper abdominal pain, and nausea or vomiting. Vision changes may develop, including flashing lights or spots, increased sensitivity to light (photophobia), blurry vision, or temporary blindness.In many cases, symptoms of preeclampsia go away within a few days after the baby is born. In severe cases, however, preeclampsia can damage the mother's organs, such as the heart, liver, and kidneys, and can lead to life-threatening complications. Extremely high blood pressure in the mother can cause bleeding in the brain (hemorrhagic stroke). The effects of high blood pressure on the brain (hypertensive encephalopathy) may also result in seizures. If seizures occur, the condition is considered to have worsened to eclampsia, which can result in coma. About 1 in 200 women with untreated preeclampsia develop eclampsia. Eclampsia can also develop without any obvious signs of preeclampsia.Between 10 and 20 percent of women with severe preeclampsia develop another potentially life-threatening complication called HELLP syndrome. HELLP stands for hemolysis (premature red blood cell breakdown), elevated liver enzyme levels, and low platelets (cells involved in blood clotting), which are the key features of this condition.Severe preeclampsia can also affect the fetus, with impairment of blood and oxygen flow leading to growth problems or stillbirth. Infants delivered early due to preeclampsia may have complications associated with prematurity, such as breathing problems caused by underdeveloped lungs.Women who have had preeclampsia have approximately twice the lifetime risk of heart disease and stroke than do women in the general population. Researchers suggest that preeclampsia, heart disease, and stroke may share common risk factors. Women who have health conditions such as obesity, hypertension, heart disease, diabetes, or kidney disease before they become pregnant have an increased risk of developing preeclampsia. Preeclampsia is most likely to occur in a woman's first pregnancy, although it can occur in subsequent pregnancies, particularly in women with other health conditions.

MalaCards based summary : Pre-Eclampsia, also known as preeclampsia, is related to eclampsia and mild pre-eclampsia, and has symptoms including edema, hyperemesis gravidarum and morning sickness. An important gene associated with Pre-Eclampsia is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Signaling events mediated by VEGFR1 and VEGFR2 and Angiogenesis (CST). The drugs Azithromycin and Clonidine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, placenta and liver, and related phenotypes are hypertension and proteinuria

Disease Ontology : 12 A hypertension occurring during pregnancy characterized by large amounts of protein in the urine (proteinuria) and edema, usually by the last trimester of pregnancy.

Wikipedia : 73 Pre-eclampsia is a disorder of pregnancy characterized by the onset of high blood pressure and often a... more...

Related Diseases for Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 774)
# Related Disease Score Top Affiliating Genes
1 eclampsia 33.9 TAC3 STOX1 PGF PEE1 NOS3 FLT1
2 mild pre-eclampsia 33.6 STOX1 PGF FLT1 ENG
3 hellp syndrome 32.9 PGF FLT1 ENG
4 preeclampsia/eclampsia 1 32.9 PEE1 NOS3
5 placental abruption 32.1 PGF NOS3 FLT1 ENG AGT
6 hypertension, essential 31.8 PGF NOS3 FLT1 ENG CORIN AGT
7 heart disease 31.3 PGF NOS3 HOTAIR H19 FLT1 ENG
8 retinal vascular disease 30.9 PGF NOS3 FLT1
9 hypertensive encephalopathy 30.9 PGF FLT1
10 exudative vitreoretinopathy 1 30.8 PGF NOS3 FLT1
11 twin-to-twin transfusion syndrome 30.7 PGF FLT1 ENG
12 microvascular complications of diabetes 5 30.7 PGF NOS3 FLT1 AGT
13 stroke, ischemic 30.6 NOS3 MALAT1 ENG AGT
14 lipoprotein quantitative trait locus 30.3 WFDC21P PGF NOS3 H19 ENG AGT
15 renal cell carcinoma, nonpapillary 29.8 TUG1 SPRY4-IT1 PGF MALAT1 HOTAIR H19
16 osteogenic sarcoma 29.6 TUG1 MALAT1 HOTAIR H19
17 myeloma, multiple 29.4 TUG1 MALAT1 HOTAIR H19
18 severe pre-eclampsia 11.9
19 preeclampsia/eclampsia 5 11.5
20 preeclampsia/eclampsia 4 11.5
21 gestational diabetes 11.3
22 preeclampsia/eclampsia 3 11.2
23 proteinuria, chronic benign 11.1
24 alpha-thalassemia 10.9
25 trichothiodystrophy 10.9
26 prothrombin thrombophilia 10.9
27 factor v leiden thrombophilia 10.9
28 diethylstilbestrol syndrome 10.9
29 placenta disease 10.7
30 neonatal anemia 10.6 PGF FLT1 ENG
31 systolic heart failure 10.6 NOS3 CORIN AGT
32 late congenital syphilis 10.6 FLT1 ENG
33 early congenital syphilis 10.6 FLT1 ENG
34 glomeruloid hemangioma 10.6 FLT1 ENG
35 cancer-associated retinopathy 10.6 PGF FLT1
36 hypertension, early-onset, autosomal dominant, with severe exacerbation in pregnancy 10.6
37 epithelioid hemangioendothelioma 10.6 PGF FLT1
38 microvascular complications of diabetes 1 10.6 PGF FLT1 AGT
39 yemenite deaf-blind hypopigmentation syndrome 10.6
40 disseminated intravascular coagulation 10.6
41 thrombocytopenia 10.5
42 placental insufficiency 10.5
43 renal artery disease 10.5 NOS3 AGT
44 malignant secondary hypertension 10.5 PGF AGT
45 thrombophilia 10.5
46 diabetes mellitus 10.5
47 acute mountain sickness 10.5 NOS3 FLT1
48 retinal detachment 10.5
49 kidney disease 10.5
50 antiphospholipid syndrome 10.5

Graphical network of the top 20 diseases related to Pre-Eclampsia:



Diseases related to Pre-Eclampsia

Symptoms & Phenotypes for Pre-Eclampsia

Human phenotypes related to Pre-Eclampsia:

58 31 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertension 58 31 hallmark (90%) Very frequent (99-80%) HP:0000822
2 proteinuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0000093
3 elevated systolic blood pressure 58 31 hallmark (90%) Very frequent (99-80%) HP:0004421
4 elevated diastolic blood pressure 58 31 hallmark (90%) Very frequent (99-80%) HP:0005117
5 abnormal placenta morphology 31 hallmark (90%) HP:0100767
6 intrauterine growth retardation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001511
7 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
8 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
9 abnormality of vision 58 31 occasional (7.5%) Occasional (29-5%) HP:0000504
10 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
11 small for gestational age 58 31 occasional (7.5%) Occasional (29-5%) HP:0001518
12 abnormality of the hepatic vasculature 58 31 occasional (7.5%) Occasional (29-5%) HP:0006707
13 increased body mass index 58 31 occasional (7.5%) Occasional (29-5%) HP:0031418
14 sleep disturbance 58 31 very rare (1%) Very rare (<4-1%) HP:0002360
15 type i diabetes mellitus 58 31 very rare (1%) Very rare (<4-1%) HP:0100651
16 autoimmunity 58 31 very rare (1%) Very rare (<4-1%) HP:0002960
17 thrombocytopenia 58 31 very rare (1%) Very rare (<4-1%) HP:0001873
18 polycystic ovaries 58 31 very rare (1%) Very rare (<4-1%) HP:0000147
19 chronic kidney disease 58 31 very rare (1%) Very rare (<4-1%) HP:0012622
20 acute kidney injury 58 31 very rare (1%) Very rare (<4-1%) HP:0001919
21 elevated serum creatinine 58 31 very rare (1%) Very rare (<4-1%) HP:0003259
22 helicobacter pylori infection 58 31 very rare (1%) Very rare (<4-1%) HP:0005202
23 abnormality of the kidney 58 Occasional (29-5%)
24 abnormality of the nervous system 58 Occasional (29-5%)
25 abnormality of the placenta 58 Very frequent (99-80%)

UMLS symptoms related to Pre-Eclampsia:


edema; hyperemesis gravidarum; morning sickness

Drugs & Therapeutics for Pre-Eclampsia

Drugs for Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4 83905-01-5 55185 447043
2
Clonidine Approved Phase 4 4205-90-7 2803
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
5
Captopril Approved Phase 4 62571-86-2 44093
6
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
7
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
8
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
9
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Methyldopa Approved Phase 4 555-30-6 38853
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Labetalol Approved Phase 4 36894-69-6 3869
15
Nifedipine Approved Phase 4 21829-25-4 4485
16
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
17
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
18
Enalaprilat Approved Phase 4 76420-72-9 6917719
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
20
Ephedrine Approved Phase 4 299-42-3 9294
21
Pseudoephedrine Approved Phase 4 90-82-4 7028
22
Phenylephrine Approved Phase 4 59-42-7 6041
23
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
24 Anti-Bacterial Agents Phase 4
25 isosorbide-5-mononitrate Phase 4
26 Vasodilator Agents Phase 4
27 Antihypertensive Agents Phase 4
28 Sympatholytics Phase 4
29 Hypoglycemic Agents Phase 4
30 Adrenergic alpha-1 Receptor Antagonists Phase 4
31 Adrenergic Antagonists Phase 4
32 Adrenergic beta-Antagonists Phase 4
33 Adrenergic alpha-Antagonists Phase 4
34 Angiotensin-Converting Enzyme Inhibitors Phase 4
35 Vaccines Phase 4
36 Anesthetics Phase 4
37 Anticonvulsants Phase 4
38 Neurotransmitter Agents Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Adrenergic Agonists Phase 4
41 Adrenergic Agents Phase 4
42 Protective Agents Phase 4
43 Sympathomimetics Phase 4
44 Respiratory System Agents Phase 4
45 Cardiotonic Agents Phase 4
46 Central Nervous System Stimulants Phase 4
47 Vasoconstrictor Agents Phase 4
48 Nasal Decongestants Phase 4
49 Mydriatics Phase 4
50
Dinoprostone Approved Phase 3 363-24-6 5280360

Interventional clinical trials:

(show top 50) (show all 584)
# Name Status NCT ID Phase Drugs
1 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
2 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
3 Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial) Unknown status NCT00117546 Phase 4 alpha methyldopa
4 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
5 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
6 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
7 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Unknown status NCT02911701 Phase 4 Acetaminophen;Ibuprofen
8 Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial Unknown status NCT03233880 Phase 4 Azithromycin 1gm
9 Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension Unknown status NCT03449277 Phase 4 Oral Tablet
10 Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy Unknown status NCT03237000 Phase 4 MgSO4
11 A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Completed NCT02891174 Phase 4 Ibuprofen;Acetaminophen
12 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Completed NCT01912677 Phase 4 Nifedipine;Labetalol;Methyldopa
13 Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia Completed NCT01352234 Phase 4 Acetylsalicylic Acid 160 mg;Acetylsalicylic Acid 80 mg
14 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
15 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
16 Treatment Approaches to Preeclampsia Completed NCT01030627 Phase 4
17 Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia Completed NCT02699827 Phase 4 Levobupivacaine hydrochloride;Magnesium sulphate;Saline 0.9%
18 Randomized Trial of Magnesium Sulfate in Obese Preeclamptic Women Completed NCT02835339 Phase 4 Magnesium sulfate 4g loading dose, 1g/hr infusion;Magnesium sulfate 6g loading dose, 2g/hr infusion
19 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
20 Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
21 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
22 Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia Completed NCT03171480 Phase 4 Monoket Pill
23 An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Completed NCT03674606 Phase 4 Low dose aspirin
24 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
25 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed NCT01972659 Phase 4 placebo;Magnesium Sulphate;sugammadex
26 Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients Completed NCT03506724 Phase 4 Nifedipine;Labetalol
27 Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia Recruiting NCT04797949 Phase 4 Low-dose aspirin
28 A Randomized Trial Comparing Oral Misoprostol Alone With Oral Misoprostol Followed by Oxytocin in Women Induced for Hypertension of Pregnancy Recruiting NCT03749902 Phase 4 Oral misoprostol;Oxytocin
29 The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
30 Effect of Non-steroidal Anti-inflammatory Use on Blood Pressure in Women With Hypertensive Disorders of Pregnancy: A Randomized Open Label Trial Recruiting NCT03824119 Phase 4 Ibuprofen 600 mg
31 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Recruiting NCT04392375 Phase 4 Nifedipine 30 MG;Placebos
32 Aspirin to Prevent Cardiac Dysfunction in Preeclampsia Recruiting NCT04479072 Phase 4 Aspirin 81 mg;Placebo
33 Efficacy of 17-Hydroxyprogesterone Caproate in Expectantly Managed Early-onset Preeclampsia: A Randomized Controlled Study Recruiting NCT04077853 Phase 4 17 Hydroxyprogesterone Capronate
34 Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus Recruiting NCT03570632 Phase 4 Metformin
35 A Randomized Controlled Trial Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Recruiting NCT04236258 Phase 4 NIFEdipine ER;Enalapril
36 Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial Recruiting NCT02531490 Phase 4 Labetalol;Nifedipine;Methyldopa
37 Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies--A Multicenter, Prospective, Open, Randomized, Controlled Clinical Trial Recruiting NCT04051567 Phase 4 Aspirin 100mg
38 Postpartum Management of Gestational Hypertensive Disorders Using Furosemide: A Randomized Controlled Trial Enrolling by invitation NCT04343235 Phase 4 furosemide;labetalol
39 Lignocaine Nebulization for Attenuation of Intubation Stress Response in Patients With Severe Pre-eclampsia: a Prospective Double-blinded Placebo-controlled Trial Not yet recruiting NCT04441073 Phase 4 Lignocaine;Placebo
40 A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort Not yet recruiting NCT04631627 Phase 4 Aspirin
41 A Prospective Randomized Clinical Research Trial Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 and Those Receiving Tdap Vaccinations at Week 36 Not yet recruiting NCT04424693 Phase 4 Tdap Vaccine Administration
42 The Effectiveness of Low-dose Aspirin on Preventing Pre-eclampsia in High-risks Pregnant Women Not yet recruiting NCT04656665 Phase 4 Aspirin
43 Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily? Terminated NCT03595982 Phase 4 Procardia XL 30Mg;Procardia XL 60Mg
44 Acute Control of Chronic Hypertension in Preeclampsia Terminated NCT03877692 Phase 4 Experimental dosing of labetalol
45 Acute Labetalol Use in Preeclampsia Randomized Trial Terminated NCT03872336 Phase 4 Experimental labetalol dose
46 Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
47 Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia Terminated NCT02025426 Phase 4 Phenylephrine;Ephedrine
48 A Pragmatic Randomized Study Comparing 81 mg Aspirin Versus 162 mg Aspirin in the Prevention of Preeclampsia During Pregnancy Withdrawn NCT04158830 Phase 4 Aspirin 81 mg Enteric Coated Tab - 1 tablet;Aspirin 81 mg Enteric Coated Tab - 2 tablets
49 Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
50 Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia (4P) - a Randomised, Placebo-controlled, Double-blind Clinical Trial Unknown status NCT02007837 Phase 3 Combined aspirin and multinutrient supplement

Search NIH Clinical Center for Pre-Eclampsia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Magnesium Sulfate

Cochrane evidence based reviews: pre-eclampsia

Genetic Tests for Pre-Eclampsia

Genetic tests related to Pre-Eclampsia:

# Genetic test Affiliating Genes
1 Preeclampsia 29
2 Hypertension, Pregnancy-Induced, Susceptibility to 29

Anatomical Context for Pre-Eclampsia

MalaCards organs/tissues related to Pre-Eclampsia:

40
Endothelial, Placenta, Liver, Kidney, Heart, Brain, Thyroid

Publications for Pre-Eclampsia

Articles related to Pre-Eclampsia:

(show top 50) (show all 32480)
# Title Authors PMID Year
1
The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. 54 61 6
16059745 2005
2
The missense Glu298Asp variant of the endothelial nitric oxide synthase gene is strongly associated with placental abruption. 6 61 54
11354626 2001
3
Endothelial nitric oxide synthase gene (NOS3) variant and hypertension in pregnancy. 6 61
11745998 2001
4
Angiotensinogen: a candidate gene involved in preeclampsia? 6 61
8348146 1993
5
A molecular variant of angiotensinogen associated with preeclampsia. 6 61
8513325 1993
6
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. 6
17165044 2007
7
Genetic association between endothelial nitric oxide synthase and Alzheimer disease. 6
16813604 2006
8
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. 6
15007011 2004
9
Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. 6
11394896 2001
10
NOS3 polymorphism not associated with Alzheimer's disease in Japanese. 6
11026457 2000
11
A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK. 6
10510054 1999
12
Association between Alzheimer's disease and the NOS3 gene. 6
10514107 1999
13
The Glu-298-->Asp (894G-->T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. 6
10475066 1999
14
Coronary artery disease is not associated with the E298-->D variant of the constitutive, endothelial nitric oxide synthase gene. 6
9894802 1998
15
Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population. 6
9831339 1998
16
A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. 6
9737779 1998
17
Angiotensinogen gene and hypertension in Chinese. 6
9421481 1998
18
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 6
9259580 1997
19
Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. 6
7649545 1995
20
The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. 6
7883995 1995
21
Rapid detection of the hypertension-associated Met235-->Thr allele of the human angiotensinogen gene. 6
8518804 1993
22
Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human trophoblast. 61 54
20237132 2010
23
Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. 54 61
19269632 2010
24
Soluble endoglin in preeclamptic patients with or without HELLP syndrome. 54 61
20430360 2010
25
Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. 61 54
20374043 2010
26
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. 61 54
20205159 2010
27
The association between preeclampsia and placental disruption induced by chorionic villous sampling. 61 54
20509159 2010
28
Circulating angiogenic factors and their association with birth outcomes in preeclampsia. 54 61
20224572 2010
29
Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. 61 54
19916874 2010
30
Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. 54 61
20206155 2010
31
Nicotine suppresses interleukin-6 production from vascular endothelial cells: a possible therapeutic role of nicotine for preeclampsia. 54 61
20220107 2010
32
Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. 54 61
20502295 2010
33
Relation between first trimester maternal serum leptin levels and body mass index in normotensive and pre-eclamptic pregnancies--role of leptin as a marker of pre-eclampsia: a prospective case-control study. 61 54
20050765 2010
34
High levels of human chorionic gonadotropin (hCG) correlate with increased aquaporin-9 (AQP9) expression in explants from human preeclamptic placenta. 54 61
20220109 2010
35
Effects of labor on placental expression of superoxide dismutases in preeclampsia. 61 54
20226522 2010
36
Allelic variations in angiogenic pathway genes are associated with preeclampsia. 61 54
20223440 2010
37
Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. 61 54
20131286 2010
38
Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. 54 61
20150910 2010
39
MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. 54 61
20452491 2010
40
Differential expression and distribution of placental glutathione peroxidases 1, 3 and 4 in normal and preeclamptic pregnancy. 54 61
20303587 2010
41
Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development. 54 61
20002457 2010
42
Leptin gene (TTTC)(n) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy. 54 61
20070288 2010
43
Differential expression of VE-cadherin and VEGFR2 in placental syncytiotrophoblast during preeclampsia - New perspectives to explain the pathophysiology. 61 54
20167365 2010
44
VEGF in the muscular layer of placental blood vessels: immuno-expression in preeclampsia and intrauterine growth restriction and its association with the antioxidant status. 61 54
20184549 2010
45
A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity. 61 54
20130210 2010
46
Early-pregnancy soluble Fas levels in idiopathic small-for-gestational-age pregnancies. 61 54
20207247 2010
47
The 3'-untranslated region of the HLA-G gene in relation to pre-eclampsia: revisited. 54 61
20070604 2010
48
Role of inflammatory cytokines and eNOS gene polymorphism in pathophysiology of pre-eclampsia. 54 61
20047583 2010
49
The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. 61 54
20074261 2010
50
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. 54 61
20101671 2010

Variations for Pre-Eclampsia

ClinVar genetic disease variations for Pre-Eclampsia:

6 (show top 50) (show all 75)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NOS3 NM_000603.5(NOS3):c.894T>G (p.Asp298Glu) SNV risk factor 14015 rs1799983 GRCh37: 7:150696111-150696111
GRCh38: 7:150999023-150999023
2 AGT NM_000029.4(AGT):c.803T>C (p.Met268Thr) SNV risk factor 18068 rs699 GRCh37: 1:230845794-230845794
GRCh38: 1:230710048-230710048
3 NSD1 NM_022455.4(NSD1):c.6050G>A (p.Arg2017Gln) SNV Likely pathogenic 159398 rs587784177 GRCh37: 5:176710828-176710828
GRCh38: 5:177283827-177283827
4 MEGF6 and overlap with 1 gene(s) Duplication not provided 156727 GRCh37: 1:3411413-3431235
GRCh38: 1:3494849-3514671
5 overlap with 3 genes Deletion not provided 156753 GRCh37: 1:145625979-145762959
GRCh38:
6 KIF26B NM_018012.4(KIF26B):c.1166+53868_1166+59172del Deletion not provided 156775 GRCh37: 1:245636915-245642219
GRCh38: 1:245473613-245478917
7 SOX11 Duplication not provided 156778 GRCh37: 2:4677905-5958997
GRCh38:
8 LOC730100 NR_135237.1(LOC730100):n.754-62628_754-62323del Deletion not provided 156787 rs1553354646 GRCh37: 2:51926598-51926903
GRCh38: 2:51699460-51699765
9 REV1 NM_016316.4(REV1):c.351-3232_513dup Duplication not provided 156801 GRCh37: 2:100055762-100055763
GRCh38: 2:99439300-99439301
10 LRP1B NM_018557.2(LRP1B):c.344-65793_344-61550del Deletion not provided 156805 GRCh37: 2:142073760-142078003
GRCh38: 2:141316191-141320434
11 BAZ2B and overlap with 1 gene(s) NM_001282805.1(MARCH7):c.-247472_-1723dup Duplication not provided 156809 GRCh37: 2:160321788-160567537
GRCh38: 2:159465277-159711026
12 ACSL3 Duplication not provided 156824 GRCh37: 2:223798501-223823141
GRCh38: 2:222933783-222958423
13 TM4SF20 NM_024795.3(TM4SF20):c.-14304_183+492dup Duplication not provided 156825 GRCh37: 2:228243310-228258288
GRCh38: 2:227378594-227393572
14 overlap with 5 genes NR_110592.1(LINC01238):n.972-495_131503del Deletion not provided 156831 GRCh37: 2:242917734-243048760
GRCh38: 2:241975583-242106609
15 ARPP21 Duplication not provided 156845 GRCh37: 3:35826707-35902885
GRCh38: 3:35785215-35861393
16 CTDSPL NM_001008392.1(CTDSPL):c.80-8666_80-2299del Deletion not provided 156846 GRCh37: 3:37979882-37986249
GRCh38: 3:37938391-37944758
17 SFMBT1 NM_016329.4(SFMBT1):c.-130-31769_-130-30020del Deletion not provided 156849 GRCh37: 3:53033294-53035043
GRCh38: 3:52999278-53001027
18 overlap with 2 genes Deletion not provided 156868 GRCh37: 3:75428675-75605157
GRCh38: 3:75379524-75556006
19 overlap with 5 genes NR_031714.1(MIR1324):n.-251239_47012del Deletion not provided 156869 GRCh37: 3:75428675-75726925
GRCh38: 3:75379524-75677774
20 overlap with 2 genes Duplication not provided 156877 GRCh37: 3:100351696-100437892
GRCh38: 3:100632852-100719048
21 LINC01322 NR_125764.1(LINC01322):n.201-50931_201-19041del Deletion not provided 156896 GRCh37: 3:165041116-165073006
GRCh38: 3:165323328-165355218
22 NLGN1 NM_014932.4(NLGN1):c.-320-82616_-320-21032dup Duplication not provided 156899 GRCh37: 3:173239453-173301037
GRCh38: 3:173521663-173583247
23 ARHGAP24 NM_001025616.2(ARHGAP24):c.-186452_-21+35669dup Duplication not provided 156924 GRCh37: 4:86210281-86432381
GRCh38: 4:85289128-85511228
24 ZDHHC11 Deletion not provided 156952 GRCh37: 5:788646-840717
GRCh38: 5:788531-840602
25 ZDHHC11 Deletion not provided 156953 GRCh37: 5:788646-821726
GRCh38: 5:788531-821611
26 overlap with 2 genes Deletion not provided 156966 GRCh37: 5:9902403-9924597
GRCh38: 5:9902291-9924485
27 LOC101927078 and overlap with 1 gene(s) Deletion not provided 156994 GRCh37: 5:113874136-113986223
GRCh38: 5:114538439-114650526
28 overlap with 6 genes NR_002812.3(HCG26):n.-83887_14635dup Duplication not provided 157007 GRCh37: 6:31355119-31453640
GRCh38: 6:31387342-31485863
29 NHSL1 Deletion not provided 157028 GRCh37: 6:138909908-138929434
GRCh38: 6:138588771-138608297
30 AKAP12 NM_005100.4(AKAP12):c.163-8647_163-5271del Deletion not provided 157031 GRCh37: 6:151618235-151621611
GRCh38: 6:151297100-151300476
31 VWDE Deletion not provided 157040 GRCh37: 7:12418602-12422721
GRCh38: 7:12378976-12383095
32 ZNF716 Duplication not provided 157054 GRCh37: 7:57481104-57621951
GRCh38:
33 IMMP2L NM_001244606.1(IMMP2L):c.239+53584_239+101346del Deletion not provided 157068 GRCh37: 7:111025948-111073710
GRCh38: 7:111385892-111433654
34 MGAM Deletion not provided 157072 GRCh37: 7:141774290-141793419
GRCh38: 7:142074490-142093619
35 MTUS1 NM_001001924.2(MTUS1):c.2288-795_2449+390del Deletion not provided 157106 GRCh37: 8:17580791-17582137
GRCh38: 8:17723282-17724628
36 overlap with 3 genes Duplication not provided 157161 GRCh37: 10:47049547-47940417
GRCh38:
37 NRG3 NM_001010848.3(NRG3):c.824-173790_824-159316del Deletion not provided 157180 GRCh37: 10:83944705-83959179
GRCh38: 10:82184949-82199423
38 overlap with 3 genes Duplication not provided 157191 GRCh37: 10:135252347-135378802
GRCh38: 10:133438843-133565298
39 ASCL3 Deletion not provided 157195 GRCh37: 11:8959020-8964938
GRCh38: 11:8937473-8943391
40 OR4C12 Duplication not provided 157204 GRCh37: 11:49977336-50668400
GRCh38:
41 overlap with 3 genes NM_001004708.1(OR4D6):c.-19514_20175del Deletion not provided 157205 GRCh37: 11:59204920-59244608
GRCh38: 11:59437447-59477135
42 overlap with 3 genes NM_001267803.1(PAAF1):c.*451_*70114dup Duplication not provided 157207 GRCh37: 11:73638858-73708521
GRCh38: 11:73927813-73997476
43 PCF11 Duplication not provided 157217 GRCh37: 11:82865518-82876270
GRCh38: 11:83154476-83165228
44 CACNA1C NM_000719.6(CACNA1C):c.477+16040_477+23328del Deletion not provided 157232 GRCh37: 12:2245636-2252924
GRCh38: 12:2136470-2143758
45 overlap with 5 genes Duplication not provided 157237 GRCh37: 12:7930171-8102386
GRCh38: 12:7777575-7949790
46 LMNTD1 NM_001145728.2(LMNTD1):c.*22+2227_*22+7996del Deletion not provided 157244 GRCh37: 12:25648676-25654445
GRCh38: 12:25495742-25501511
47 overlap with 2 genes Duplication not provided 157255 GRCh37: 12:63942649-64118558
GRCh38: 12:63548869-63724778
48 SCARB1 GRCh37/hg19 12q24.31(chr12:125260645-125321461)x3 copy number gain not provided 221855 GRCh37: 12:125260645-125321461
GRCh38:
49 NRDE2 Duplication not provided 157320 GRCh37: 14:90788934-90802050
GRCh38: 14:90322590-90335706
50 NIPA1 Deletion not provided 157329 GRCh37: 15:23084443-23114374
GRCh38:

Copy number variations for Pre-Eclampsia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44882 10 64500000 74900000 Loss STOX1 Preeclampsia

Expression for Pre-Eclampsia

Search GEO for disease gene expression data for Pre-Eclampsia.

Pathways for Pre-Eclampsia

Pathways related to Pre-Eclampsia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.1 PGF NOS3 FLT1
2 10.75 NOS3 FLT1 ENG
3 10.64 NOS3 FLT1
4
Show member pathways
10.36 PGF FLT1

GO Terms for Pre-Eclampsia

Biological processes related to Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vasodilation GO:0042311 9.46 NOS3 AGT
2 positive regulation of blood pressure GO:0045777 9.43 TAC3 AGT
3 female pregnancy GO:0007565 9.43 TAC3 CORIN AGT
4 nitric oxide mediated signal transduction GO:0007263 9.4 NOS3 AGT
5 endocardial cushion morphogenesis GO:0003203 9.37 NOS3 ENG
6 regulation of blood pressure GO:0008217 9.33 NOS3 CORIN AGT
7 vascular endothelial growth factor signaling pathway GO:0038084 9.32 PGF FLT1
8 positive regulation of angiogenesis GO:0045766 9.26 PGF NOS3 FLT1 ENG
9 regulation of renal sodium excretion GO:0035813 8.62 CORIN AGT

Sources for Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....